Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Oklahoma
This is a pilot clinical trial with 30 patients with either: 1) suspected prostate cancer (based on elevated PSA or abnormal digital rectal exam (DRE), or 2) known low-risk prostate cancer being managed with active surveillance.
Enrolled patients will undergo MRI fusion biopsy and standard-template 12 core TRUS biopsy as the standard-of-care. Patients will also undergo micro-ultrasound evaluation and targeted biopsy if lesions are identified. Detection rates of clinically significant lesions by ExactVu and by MRI will be compared.
Age
18–99
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1. Patients scheduled to undergo biopsy and with one of the following:
* Men with suspicion of prostate cancer
* Men on active surveillance
2. Age ≥18 \[30\]
3. Have available multiparametric prostate MRI
4. Able to provide written, informed consent
5. No significant medical illness which in the opinion of the Investigator would preclude entry to study procedures
6. Be willing and able to comply with scheduled visits
You may not be if
1. Previously confirmed prostate cancer diagnosis with Grade Group \>= 2
2. Unable to undergo prostate biopsy
3. Prostate MRI unable to be evaluated using the PI-RADS v2 criteria
4. Men with contraindication for MRI or a prostate biopsy
5. Prostate biopsy within 8 weeks prior to mpMRI.
6. Any history of prostate treatment
Clareo Health | MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
